Skip to main content
Publications
Pijuan-Domenech A, Pineda V, Ferreira-Gonzalez I, Marsal JR, Castro Miguel A, Sureda-Barbosa C, Valente F, Miranda B, Subirana-Domenech T, Dos-Subira L, Garcia-Dorado D, Casaldaliga-Ferrer J. Diagnosing abnormal end-diastolic forward flow: new definition proposal based on healthy controls. IJC CHD. 2021 Aug;4:100140. doi: 10.1016/j.ijcchd.2021.100140
Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, Heidbreder C. Recovery from Opioid Use Disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study. J Addict Med. 2020 Sep;14(5):e233-40. doi: 10.1097/ADM.0000000000000647
Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study. J Addict Med. 2019 Nov;13(6):442-9. doi: 10.1097/ADM.0000000000000517.
Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez-Salas N, Martin-Richard M, Alonso-Orduna V, Vera R, Gallegeo J, Capdevila J, Salud A, Nogue M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019 Aug 29;5(11):1566-73. doi: 10.1001/jamaoncol.2019.2294
Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SE. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1215
Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Gholamrezaee M, Magistretti P, Aubry JM, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Kutalik Z, Conus P, Eap CB. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. J Clin Psychopharmacol. 2015 Oct;35(5):544-52. doi: 10.1097/JCP.0000000000000388